Faculty of Science, Universiti Brunei Darussalam, Jln Tungku Link, Gadong, Bandar Seri Begawan, Brunei Darussalam.
PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jln Tungku Link, Bandar Seri Begawan, Brunei Darussalam.
BMC Cancer. 2024 Aug 12;24(1):994. doi: 10.1186/s12885-024-12725-5.
Non-Hodgkin lymphoma (NHL) has been identified as a significant contributor to the cancer burden. This study investigates the incidence, mortality, and survival trends of NHL cancer in Brunei Darussalam from 2011 to 2020.
This is a registry-based retrospective study using de-identified data from the Brunei Darussalam Cancer Registry on patients diagnosed with NHL from 2011 to 2020 based on the ICD-10 codes C82-86. Statistical methods include descriptive statistics, age-specific and age-standardised incidence (ASIR) and mortality rates (ASMR), and joinpoint regression for trend analysis. Survival analysis was conducted using Kaplan-Meier plots, log-rank test, and Cox Proportional Hazards regression.
From 2011 to 2020, 330 patients were diagnosed with NHL. The majority of patients were males (51.8%) and of Malay descent (82.7%). The age group most diagnosed was 55-74 years (42.3%), with a mean age at diagnosis being 55.1 years. The ASIRs were 12.12 for males and 10.39 per 100,000 for females; ASMRs were 6.11 for males and 4.76 per 100,000 for females. Diffuse large B-cell lymphoma was the most prevalent subtype, accounting for 39.1% of cases. The overall 5-year survival rate was 61.2%, with lower rates observed in older patients and those diagnosed at distant metastasis stage. Furthermore, older age and advanced stage diagnosis significantly increased mortality risk. NHL incidence and mortality rates in Brunei Darussalam remain stable over the period of 10 years, but highlights significant disparities in gender and age.
The findings emphasize the importance of early detection and tailored treatments, especially for high-risk groups, in managing NHL's burden. These insights underline the need for focused healthcare strategies and continued research to address NHL's challenges.
非霍奇金淋巴瘤（NHL）已被确定为癌症负担的重要因素。本研究调查了 2011 年至 2020 年文莱达鲁萨兰国 NHL 癌症的发病率、死亡率和生存趋势。
这是一项基于登记的回顾性研究，使用文莱达鲁萨兰国癌症登记处的匿名数据，根据 ICD-10 代码 C82-86，对 2011 年至 2020 年期间诊断为 NHL 的患者进行分析。统计方法包括描述性统计、年龄特异性和年龄标准化发病率（ASIR）和死亡率（ASMR），以及用于趋势分析的连接点回归。生存分析采用 Kaplan-Meier 图、对数秩检验和 Cox 比例风险回归。
2011 年至 2020 年期间，共诊断出 330 名 NHL 患者。大多数患者为男性（51.8%），马来族裔（82.7%）。诊断最多的年龄组是 55-74 岁（42.3%），平均诊断年龄为 55.1 岁。男性的 ASIR 为 12.12/100,000，女性为 10.39/100,000；男性的 ASMR 为 6.11/100,000，女性为 4.76/100,000。弥漫性大 B 细胞淋巴瘤是最常见的亚型，占 39.1%。总体 5 年生存率为 61.2%，年龄较大和远处转移阶段诊断的患者生存率较低。此外，年龄较大和晚期诊断显著增加了死亡风险。文莱达鲁萨兰国 NHL 的发病率和死亡率在 10 年期间保持稳定，但在性别和年龄方面存在显著差异。
这些发现强调了早期发现和针对性治疗的重要性，特别是对高危人群，以管理 NHL 的负担。这些结果突显了制定重点医疗保健策略和持续研究以应对 NHL 挑战的必要性。
